Home › Islet Cell Adenoma › NCT05746182

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Histologically confirmed PanNEN.

   a. The diagnostic biopsy may have been taken from any site (primary or metastatic).
2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years).
3. Participants willing and able to comply with the study procedures.

Exclusion Criteria:

1. Inability to provide informed consent.
2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:

   1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
   2. Active hematologic malignancy.
   3. History of allogenic bone marrow transplant or stem cell transplant.

About the study

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

What is being tested

• Hereditary Cancer Panel (diagnostic test)

Sponsor: University of California, San Francisco · Participants: 300 · Started: Apr 7, 2023

Contact the study team

• Bryan Le · Phone: (415) 502-6313

Official record on ClinicalTrials.gov — NCT05746182

Locations in the U.S.

Conditions

• Islet Cell Adenoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.